Skip to main content
Caplight Logo









Evommune

Evommune

Public
Palo Alto, CaliforniaBiotechhttps://www.evommune.com

Evommune is now publicly traded

The data on this page reflects Evommune's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Last Round

Series C

Oct 31, 2024

Total Funding Raised

$318M

Company Overview

Evommune is a biotechnology company that develops innovative treatments targeting the root causes of inflammatory diseases to enhance patient quality of life.

Sector

Biotech

Verticals

Life Sciences

AI Layer

Non-AI

Keywords

therapies for immune-mediated inflammatory diseasehuman tissue-based drug discovery platformsmall molecule and biologic drug developmentclinical-stage biopharmaceutical pipelinetherapeutics for atopic dermatitistherapeutics for chronic urticariaMRGPRX2 antagonistmast cell-mediated disease therapyIL-18 fusion proteinIRAK4 inhibitorPKCθ inhibitor programRORγt inhibitor program

Evommune Comparables

Compare Evommune with similar companies based on industry and business-model similarity.

Evommune comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Attovia Therapeutics
82%
Jasper Therapeutics
80%
Septerna
80%

Evommune Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series COct 31, 2024
Series BJun 28, 2023
Series BMar 28, 2023
Series ASep 9, 2021
SeedNov 18, 2020

Evommune Investors

Notable investors and investment history

Evommune investors
InvestorRounds
Avego ManagementSeries C
SymBiosis Capital ManagementSeries C, Series B
ADAR1 Capital ManagementSeries C
RA Capital ManagementSeries C
EQT Life SciencesSeries C, Series A, Series B
Amplitude VenturesSeries B, Series C
Andera PartnersSeries B, Series C, Series A

Evommune Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Evommune Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersPalo Alto, California
Employee Range68
Year Founded2020
Last FundingOct 31, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?